Article info

Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
Free

Authors

  1. Correspondence to Dr Larissa Valor-Méndez, Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany; larissa.valormendez{at}uk-erlangen.de
View Full Text

Citation

Valor-Méndez L, Tascilar K, Simon D, et al
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’

Publication history

  • Received May 31, 2021
  • Accepted June 3, 2021
  • First published June 29, 2021.
Online issue publication 
September 13, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.